Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique最新文献

{"title":"Fast neutron radiotherapy and boron neutron capture therapy: application to a human melanoma test system","authors":"G.E. Laramore, R. Risler, T.W. Griffin, P. Wootton, D.S. Wilbur","doi":"10.1016/0924-4212(96)84911-5","DOIUrl":"10.1016/0924-4212(96)84911-5","url":null,"abstract":"<div><p>Fast neutron radiotherapy has proven to be an effective form of treatment in a selected subset of tumors (salivary gland tumors, sarcomas, and locally-advanced prostate cancer), but has not proven to be more beneficial than conventional photon irradiation for the majority of tumor types upon which it has been tested. Normal tissue tolerance limits preclude simply further escalating the neutron dose. Boron neutron capture (BNC) provides a way of selectively augmenting the radiation dose to the tumor. This process is described, and cell culture and animal model data reviewed. An irradiation configuration was developed where an enhancement of 2·10<sup>−3</sup> for l<!--> <!-->μg of <sup>10</sup>B per gram of tissue was achieved. This is similar to the enhancement achievable in the center of a 20<!--> <!-->×<!--> <!-->20 cm field envisioned for future applications such as metastases in the brain. A boron concentration of 50<!--> <!-->μg per gram of tumor tissue leads to a 10% increase in the delivered physical dose in this scenario. The first human test of BNC enhancement of a fast neutron radiotherapy beam using pharmacologically-acceptable doses of orally-administered, <sup>10</sup>B-enriched, <em>L-para</em>-boronophenylalanine is reported. An enhancement of tumor response was demonstrated for a melanoma skin nodule test system. Boron levels achieved in blood, skin, and tumors are presented. Future research plans are discussed.</p></div><div><p>La radiothérapie par neutrons rapides a fait la preuve de son efficacité dans le traitement de quelques tumeurs selectionnées (tumeurs des glandes salivaires, sarcomes et cancers localement évolués de la prostate). Elle ne présente pas d’avantage démontré par rapport aux rayons X dans la majorité des autres tumeurs évoluées. Les tissus sains en limitent souvent l’utilisation en ne permettant pas de donner les doses de neutrons nécessaires au contrôle local. La capture des neutrons par le bore (CNB) permet d’augmenter la dose à la tumeur de manière sélective. Ce processus est décrit et les résultats obtenus en culture cellulaire ou in vivo sur modèle animal sont revus. Une configuration d’irradiation a été développée dans laquelle la dose est augmentée de 2<!--> <!-->x<!--> <!-->10<sup>−3</sup> pour 1 μg de <sup>l0</sup>B par gramme de tissu. Ce résultat est comparable à celui obtenu au centre d’un champs 20<!--> <!-->×<!--> <!-->20 cm qui pourrait être utilisé en clinique pour des métastases cérébrales, par exemple. Dans ce cas, une concentration de 50<!--> <!-->μg par gramme de tissu produit une augmentation de dose de 10%. Le premier essai clinique a évalué l’administration orale d’une molécule de <em>l-para</em>-borophénylalanine enrichie en <sup>10</sup>B avant un traitement par neutrons rapides pour un mélanome malin. Une augmentation de la réponse tumorale a été constatée au niveau d’un nodule cutané. Les niveaux de concentration de bore dans le sang, la peau et la tumeur, sont rapportés. Les ","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 ","pages":"Pages 191s-197s"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0924-4212(96)84911-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19912797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphomes non hodgkiniens de l'adulte. Stratégie thérapeutique","authors":"JP Le Bourgeois , F Reyes","doi":"10.1016/S0924-4212(97)86062-8","DOIUrl":"10.1016/S0924-4212(97)86062-8","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Pages 258-264"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86062-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56283167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curiethérapie postopératoire à bas débit de dose des adénocarcinomes de ï'endomètre","authors":"C Charra-Brunaud, D Peiffert, S Hoffstetter, C Marchai, V Beckendorf, P Bey","doi":"10.1016/S0924-4212(97)86127-0","DOIUrl":"10.1016/S0924-4212(97)86127-0","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Page 422"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86127-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56283981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P30 Aspects épidémiocliniques des cancers du col utérin. Étude comparative femme jeune versus femme âgée","authors":"A Benider, A Acharki, S Sahraoui, N Tawfiq, H Jouhadi, N Bouras, R Samlali, A Kahlain","doi":"10.1016/S0924-4212(97)86149-X","DOIUrl":"10.1016/S0924-4212(97)86149-X","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Page 430"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86149-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56284191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curiethérapie à haut débit de dose (CHDD) dans le cancer du sein: résultats à 5 ans","authors":"A Salemkour, C Hennequin, C Durdux, M Espié, S Mekias, S Delanian, M Housset, M Levardon, C Maylin","doi":"10.1016/S0924-4212(97)86122-1","DOIUrl":"10.1016/S0924-4212(97)86122-1","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Page 420"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86122-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56283402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiothérapie des métastases osseuses. Revue de la littérature","authors":"JM Simon","doi":"10.1016/S0924-4212(97)86073-2","DOIUrl":"10.1016/S0924-4212(97)86073-2","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Pages 290-298"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86073-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56283314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L'imagerie portale, pour quoi faire ?","authors":"F Mornex","doi":"10.1016/S0924-4212(97)86111-7","DOIUrl":"10.1016/S0924-4212(97)86111-7","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Pages 391-396"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86111-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56283776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P1 Mode de rechute des LNH localisés (stades I et II) en fonction des champs d'irradiation","authors":"C Hennequin, P Pautier, P Brice, C Gisselbrecht, C Maylin","doi":"10.1016/S0924-4212(97)86065-3","DOIUrl":"10.1016/S0924-4212(97)86065-3","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Page 273"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86065-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56283198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimiothérapie périopératoire des carcinomes épidermoïdes de l'hypopharynx","authors":"G Mamelle, C Domenge, F Eschwège, A.M. Leridant, B Luboinski, P Wibault","doi":"10.1016/0924-4212(96)85323-0","DOIUrl":"https://doi.org/10.1016/0924-4212(96)85323-0","url":null,"abstract":"<div><p>Le bul de cette étude prospective était de réduire le taux de récidives locales (RL), le taux de métastases à distance et ainsi d'améliorer la survie des patients. Les patients atteints d'un carcinome épidermoïde du sinus piriforme, de la margelle laryngée ou de la région rétro-crico-aryténoïdienne relevant d'une pharyngolaryngectomie totale étaient incluables dans cette étude. Le protocole prévoyait trois cures de chimiothérapie préopératoire (CDDP cisplatine 100 mg/m<sup>2</sup> j1,5-FU 1 g/m<sup>2</sup> j1 à j5) puis deux cures de la même chimiothérapie en postopératoire à j10 et j31. La radiothérapie postopératoire a été effectuée àj50. Parmi les 198 cancers de l'hypopharynx vus entre 1986 et 1989 à l'institut Gustave-Roussy, 60 ont été inclus dans ce protocole. La réponse tumorale aux trois cures initiales de chimiothérapie était: non réponse (NR): 22; réponse partielle (PR): 25; réponse complète (CR): 11: réponse non évaluable: 2. Parmi les 47 patients opérés, seulement deux pièces opératoires ont été considérées stérilisées à l'examen histologique et deux pièces avec uniquement des débris de kératine. Parmi les 39 patients ayant eu le protocole; 4 RL, 4 RL + M, 8 M, trois deuxièmes localisations au niveau des voies aérodigestives supérieures (VADS) et une leucémie aiguë myéloblastique ont été observées. Les résultats de cette étude, comparée à ceux d'une étude historique (199 patients) ayant le même délai d'observation, montrent un taux de survie identique à 2 ans, 78% contre 77% et de 42% contre 33% à 5 ans (NS).</p></div><div><p>The aim of this prospective study was to decrease the rate of locoregional recurrence (LRR) and distant metastasis (DM) with a multi-modality approach in hypopharyngeal squamous cell caracinoma (HSCC). Patients presenting with squamous cell carcinoma of the pyriform sinus, epilarynx or postcricoid area with indication of pharyngolaryngectomy, without previous treatment, distant metastasis, multiple primaries or general contraindications for surgery and chemotherapy were included in the study. Patients received three consecutive cycles of chemotherapy (CDDP cisplatinium 100 mg/m<sup>2</sup> D1. 5-FU 1 g/m<sup>2</sup> D1 to D5) before surgery, then two postoperative courses of the same chemotherapy at day 10 and 31 after surgery. Postoperative radiotherapy was initiated at day 50. Between 1986 and 1989, of 198 patients with HSCC, 60 were included in this study. Tumour response of the induction chemotherapy was: no response (NR): 22, partial response (PR): 25; complete response (CR): 11: non evaluable: 2. Forty-seven patients underwent surgery. Only two patients had no viable tumour in the surgical specimen and two others only keratin debris. Of 39 patients in which protocol treatment was respected, 4 LRR, 4 LRR + DM. 8 DM. three second head and neck primaries, and one acute myeloblastic leukemia were observed. Results were compared with those of historical series, with the same mean delay of follow up. The ","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 2","pages":"Pages 115-117"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0924-4212(96)85323-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92097998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P5 Pain palliation in patients with advanced prostate cancer metastatic to bone: preliminary results with 89SR chloride","authors":"P Rovea, B Sola, A Boidi Trotti","doi":"10.1016/S0924-4212(97)86075-6","DOIUrl":"10.1016/S0924-4212(97)86075-6","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"Page 305"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0924-4212(97)86075-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"106900553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}